Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REN001 Safety Study in Primary Mitochondrial Myopathy
NCT03862846Phase 1Terminated
- Sponsor
- Reneo Pharmaceuticals
- Start
- May 2019
- Primary completion
- Apr 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of mavodelpar in primary mitochondrial myopathy (PMM), sponsored by Reneo Pharmaceuticals. Primary endpoint: Adverse Events at 12 weeks. Started May 2019; status: terminated.
02
Drugs
mavodelpar
03
Conditions
primary mitochondrial myopathy (PMM)
Beyond the preview
Go deeper on NCT03862846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03862846.